SEARCH

SEARCH BY CITATION

References

  • Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M (2012) Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol 24: 585-591
  • Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, et al (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome. Science 341: 1233151.
  • Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A, Urbinati F, Valacca C, Scaramuzza S, Aker M, et al (2007) Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240
  • Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458
  • Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, et al (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413
  • Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, Schneider IC, Münch RC, Petznek H, Kontermann RE (2010) Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929-935
  • Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK, Philpott NJ (2007) Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15: 1947-1954
  • Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357: 1472-1475
  • Araki R, Seno S, Takenaka Y, Matsuda H (2013a) An estimation method for a cellular-state-specific gene regulatory network along tree-structured gene expression profiles. Gene 518: 17-25
  • Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, et al (2013b) Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494: 100-104
  • Arens A, Appelt J-U, Bartholomae CC, Gabriel R, Paruzynski A, Gustafson D, Cartier N, Aubourg P, Deichmann A, Glimm H (2012) Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites. Hum Gene Ther Methods 23: 111-118
  • Aronovich EL, McIvor RS, Hackett PB (2011) The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 20: R14-R20
  • Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, et al (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239
  • Banasik M, McCray P (2009) Integrase-defective lentiviral vectors: progress and applications. Gene Ther 17: 150-157
  • Barde I, Laurenti E, Verp S, Wiznerowicz M, Offner S, Viornery A, Galy A, Trumpp A, Trono D (2011) Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther 18: 1087-1097
  • Bartholomae CC, Cartier N, Hacein-Bey-Abina S, Kutschera I, Fischer A, Cavazzana-Calvo M, Aubourg P, Schmidt M, von Kalle C (2013) Integration profile of lentiviral vectors in gene therapy for X-adrenoleukodystrophy. Mol Ther 21: s106
  • Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, et al (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158
  • Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, et al (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science (New York, NY) 270: 475-480
  • Bonini C, Parmiani G (2012) When transgenes shape immunity: cancer immune-gene therapy. J Gene Med 14: 384-385
  • Boulard F, Wang X, Taylor C, Qu J, Ferro L, Karponi G, Bartido S, Giardina P, Heller G, Prockop SE, et al (2013) Safe G-CSF mobilization of thalassemia patient CD34+ cells and effective globin gene transduction for therapeutic infusion. Mol Ther 21: s25
  • Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, et al (2010) Stem-cell gene therapy for the Wiskott–Aldrich syndrome. N Engl J Med 363: 1918-1927
  • Brendel C, Hänseler W, Wohlgensinger V, Bianchi M, Tokmak S, Chen-Wichmann L, Kouzmenco E, Cesarovic N, Nicholls F, Reichenbach J, et al (2013) Human miR223 promoter as novel myelospecific promoter for CGD gene therapy. Hum Gene Ther Methods 24: 151-159
  • Brendel C, Müller-Kuller U, Schultze-Strasser S, Stein S, Chen-Wichmann L, Krattenmacher A, Kunkel H, Dillmann A, Antoniou MN, Grez M (2011) Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 19: 1018-1029
  • Brenner MK (2012) Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther 19: 818-821
  • Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817-4828
  • Brugman MH, Suerth JD, Rothe M, Suerbaum S, Schambach A, Modlich U, Kustikova O, Baum C (2013) Evaluating a LM-PCR and pyrosequencing method for the detection of clonal contribution in polyclonal retrovirally transduced samples. Hum Gene Ther Methods 24: 68-79
  • Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB, Traxler EA, Tycko J, Wojno AP, Wilson JM (2013) Lessons learned from the clinical development and market authorization of glybera. Hum Gene Ther Clin Dev 24: 55-64
  • Büning H (2013) Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med 5: 1-3
  • Büning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M (2008) Recent developments in adeno-associated virus vector technology. J Gene Med 10: 717-733
  • Burnett JC, Zaia JA, Rossi JJ (2012) Creating genetic resistance to HIV. Curr Opin Immunol 24: 625-632
  • Byrne BJ, Falk DJ, Clément N, Mah CS (2012) Gene therapy approaches for lysosomal storage disease: next-generation treatment. Hum Gene Ther 23: 808-815
  • Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ (2012) Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 120: 3635-3646
  • Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, Merella S, Nonis A, Di Serio C, Montini E, et al (2012) Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci USA 109: 15018-15023
  • Carbonaro DA, Jin X, Wang X, Yu XJ, Rozengurt N, Kaufman ML, Gjertson D, Zhou Y, Blackburn MR, Kohn DB (2012) Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction. Blood 120: 3677-3687
  • Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (New York, NY) 326: 818-823
  • Casanova JL, Fieschi C, Zhang SY, Abel L (2008) Revisiting human primary immunodeficiencies. J Intern Med 264: 115-127
  • Cattaneo R, Miest T, Shashkova EV, Barry MA (2008) Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540
  • Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B, Schmidt M, von Kalle C, Howe S, Thrasher AJ, et al (2007) Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110: 1770-1778
  • Cattoglio C, Pellin D, Rizzi E, Maruggi G, Corti G, Miselli F, Sartori D, Guffanti A, Di Serio C, Ambrosi A, et al (2010) High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 116: 5507-5517
  • Cavazza A, Moiani A, Mavilio F (2013) Mechanisms of retroviral integration and mutagenesis. Hum Gene Ther 24: 119-131
  • Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A (2012) Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol 24: 580-584
  • Cavazzana-Calvo M, Hacein-Bey S, Saint Basile, Gd, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (New York, NY) 288: 669-672
  • Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A (2005) Gene therapy for severe combined immunodeficiency. Annu Rev Med 56: 585-602
  • Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, et al (2010) Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467: 318-322
  • Charrier S, Dupre L, Scaramuzza S, Jeanson-Leh L, Blundell M, Danos O, Cattaneo F, Aiuti A, Eckenberg R, Thrasher A (2006) Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther 14: 415-428
  • Chatziandreou I, Siapati EK, Vassilopoulos G (2011) Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors. Exp Hematol 39: 643-652
  • Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Komáromy AM (2013) Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 110: E517-E525
  • Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, Rosenberg N, Somia N, King N, Friedmann T, Dunbar C, et al (2012) Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 20: 1084-1094
  • Cronin M, Stanton R, Francis K, Tangney M (2012) Bacterial vectors for imaging and cancer gene therapy: a review. Cancer Gene Ther 19: 731-740
  • Deichmann A, Brugman MH, Bartholomae CC, Schwarzwaelder K, Verstegen MM, Howe SJ, Arens A, Ott MG, Hoelzer D, Seger R (2011) Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther 19: 2031-2039
  • DeRavin SS, Choi U, Theobald N, Lee J, Wang H, Wu X, O'Connor G, Mc Vicar DW, Kang E, Gray JT, et al (2013) Lentiviral gene transfer for treatment of children >2 years old with X-linked severe combined immunodeficiency. Mol Ther 21: s118
  • Derse D, Crise B, Li Y, Princler G, Lum N, Stewart C, McGrath CF, Hughes SH, Munroe DJ, Wu X (2007) Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol 81: 6731-6741
  • Di Matteo M, Belay E, Chuah MK, Vandendriessche T (2012) Recent developments in transposon-mediated gene therapy. Expert Opin Biol Ther 12: 841-858
  • Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683
  • Doulatov S, Notta F, Laurenti E, Dick JE (2012) Hematopoiesis: a human perspective. Cell Stem Cell 10: 120-136
  • Ebina H, Kanemura Y, Suzuki Y, Urata K, Misawa N, Koyanagi Y (2012) Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir. Virology 427: 44-50
  • Elsner M, Terbish T, Jörns A, Naujok O, Wedekind D, Hedrich H-J, Lenzen S (2012) Reversal of diabetes through gene therapy of diabetic rats by hepatic insulin expression via lentiviral transduction. Mol Ther 20: 918-926
  • Felice B, Cattoglio C, Cittaro D, Testa A, Miccio A, Ferrari G, Luzi L, Recchia A, Mavilio F (2009) Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS ONE 4: e4571
  • Fischer A (2003) Human primary immunodeficiency diseases: a perspective. Nat Immunol 5: 23-30
  • Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M (2011) Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 127: 1356-1359
  • Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M (2013) Gene therapy of primary T cell immunodeficiencies. Gene 525: 170-173
  • Frecha C, Costa C, Nègre D, Amirache F, Trono D, Rio P, Bueren J, Cosset F-L, Verhoeyen E (2012) A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood 119: 1139-1150
  • Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, et al (2011) An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29: 816-823
  • Gaspar HB (2012) Gene therapy for ADA-SCID: defining the factors for successful outcome. Blood 120: 3628-3629
  • Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, Al Ghonaium A, Bayford J, Brown L, Davies EG, et al (2011) Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 3: 97ra79
  • Gaspar HB, Swift S, Thrasher AJ (2013) “ Special exemptions”: should they be put on trial? Mol Ther 21: 261-262
  • Gathmann B, Binder N, Ehl S, Kindle G (2012) The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol 167: 479-491
  • Gathmann B, Grimbacher B, Beauté J, Dudoit Y, Mahlaoui N, Fischer A, Knerr V, Kindle G (2009) The European internet-based patient and research database for primary immunodeficiencies: results 2006–2008. Clin Exp Immunol 157: 3-11
  • Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N (2012) Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20: 361-369
  • Gijsbers R, Ronen K, Vets S, Malani N, Rijck Jd, McNeely M, Bushman FD, Debyser Z (2010) LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther 18: 552-560
  • Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531-4536
  • Goebel WS, Dinauer MC (2003) Gene therapy for chronic granulomatous disease. Acta Haematol 110: 86-92
  • Grez M, Reichenbach J, Schwäble J, Seger R, Dinauer MC, Thrasher AJ (2011) Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 19: 28-35
  • Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6: 335-341
  • Gurdon JB (1962) The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 10: 622-640
  • Hacein-Bey-Abina S, Blondeau J, Caccavelli L, Charrier S, Picard C, Dal-Cortivo L, Cross G, Blanche S, Bushman F, Malani N, et al (2013) Lentiviral vector-based gene therapy for Wiskott–Alrdrich syndrome: preliminary results from the French center. Mol Ther 21: s117
  • Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, Villartay J-Pd, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, et al (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193
  • Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, NY) 302: 415-419
  • Hackett PB, Largaespada DA, Switzer KC, Cooper LJ (2013) Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 161: 265-283
  • Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon TJ, Boye SL, Flotte TR, Byrne BJ, et al (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990
  • Heydemann A, Warming S, Clendenin C, Sigrist K, Hjorth JP, Simon MC (2000) A minimal c-fes cassette directs myeloid-specific expression in transgenic mice. Blood 96: 3040-3048
  • Honig M, Albert MH, Schulz A, Sparber-Sauer M, Schutz C, Belohradsky B, Gungor T, Rojewski MT, Bode H, Pannicke U, et al (2006) Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 109: 3595-3602
  • Horowitz S, Bach F, Groshong T, Hong R, Yunis E (1975) Treatment of severe combined immunodeficiency with bone-marrow from an unrelated, mixed-leucocyte-culture-nonreactive donor. Lancet 306: 431-433
  • Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, Ridder Dd, et al (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150
  • Hu B, Dai B, Wang P (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28: 6675-6683
  • Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada K, Nakagata N, et al (2004) Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431: 997-1002
  • Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y, et al (2006) Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12: 446-451
  • Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ (2011) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124: 304-313
  • June CH, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716
  • Juntilla MM, Patil VD, Calamito M, Joshi RP, Birnbaum MJ, Koretzky GA (2010) AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood 115: 4030-4038
  • Kaeppel C, Beattie S, Fronza R, von Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, et al (2013) AAV integrates randomly into the nuclear and mitochondrial genome after LPLD gene therapy. Mol Ther 21: s104
  • Kalos M (2012) Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. Cancer Immunol Immunother 61: 127-135
  • Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73
  • Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, et al (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105
  • Kastelein JJ, Ross CJ, Hayden MR (2013) From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Hum Gene Ther 24: 472-478
  • Kaufmann KB, Brendel C, Suerth JD, Mueller-Kuller U, Chen-Wichmann L, Schwäble J, Pahujani S, Kunkel H, Schambach A, Baum C, et al (2012) Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther 21: 648-661
  • Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, et al (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261
  • Kershaw MH, Westwood JA, Darcy PK (2013) Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13: 525-541
  • Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M Nathan D-AN, Lanier BJ, et al (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102
  • Kratlian RG, Hajjar RJ (2012) Cardiac gene therapy: from concept to reality. Curr Heart Fail Rep 9: 33-39
  • Kustikova O, Fehse B, Modlich U, Yang M, Düllmann J, Kamino K, Neuhoff Nv, Schlegelberger B, Li Z, Baum C (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science (New York, NY) 308: 1171-1174
  • Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z, Baum C (2009a) Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 17: 1537-1547
  • Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z, Baum C (2009b) Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 17: 1537-1547
  • Lam P, Khan G, Stripecke R, Hui K, Kasahara N, Peng K, Guinn B (2013) The innovative evolution of cancer gene and cellular therapies. Cancer Gene Ther 20: 141-149
  • Lechman ER, Gentner B, van Galen P, Giustacchini A, Saini M, Boccalatte FE, Hiramatsu H, Restuccia U, Bachi A, Voisin V, et al (2012) Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 11: 799-811
  • Lee GK, Zeidan J, Lalezari J, Mitsuyasu R, Wang S, Giedlin M, Nichol G, Tang W, Ando D, Sekaly R-P (2013) Long term CD4 reconstitution in HIV subjects receiving ZFN CCR5 modified CD4 T-cells (SB-728-T) may be attributed to the sustained durability of the central memory T-cell subset. Mol Ther 21: s24
  • Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, Wang DJ, Assadi M, Goldfarb O, Goldman HW, et al (2012) Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 4: 165ra163
  • LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, et al (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10: 309-319
  • Li C, Goudy K, Hirsch M, Asokan A, Fan Y, Alexander J, Sun J, Monahan P, Seiber D, Sidney J (2009) Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci USA 106: 10770-10774
  • Loew R, Meyer Y, Kuehlcke K, Gama-Norton L, Wirth D, Hauser H, Stein S, Grez M, Thornhill S, Thrasher A, et al (2010) A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther 17: 272-280
  • Lombardo A, Cesana D, Genovese P, Di Stefano B, Provasi E, Colombo DF, Neri M, Magnani Z, Cantore A, Lo Riso P, et al (2011) Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 8: 861-869
  • Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee Y-L, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD (2007) Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 25: 1298-1306
  • Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C (2010) Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther 21: 241-250
  • Maetzig T, Galla M, Baum C, Schambach A (2011) Gammaretroviral vectors: biology, technology and application. Viruses 3: 677-713
  • Maguire AM, Simonelli F, Pierce EA, Pugh EN, Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, et al (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248
  • Malech HL (1999) Progress in gene therapy for chronic granulomatous disease. J Infect Dis 179: S318-S325
  • Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, et al (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94: 12133-12138
  • Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347
  • Marangoni F, Bosticardo M, Charrier S, Draghici E, Locci M, Scaramuzza S, Panaroni C, Ponzoni M, Sanvito F, Doglioni C, et al (2009) Evidence for long-term efficacy and safety of gene therapy for Wiskott–Aldrich syndrome in preclinical models. Mol Ther 17: 1073-1082
  • Mátrai J, Chuah MK, VandenDriessche T (2010) Recent advances in lentiviral vector development and applications. Mol Ther 18: 477-490
  • Mavilio F (2012) Gene therapies need new development models. Nature 490: 7
  • Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, Maruggi G, Ferrari G, Provasi E, Bonini C, et al (2006) Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12: 1397-1402
  • Mays LE, Wilson JM (2011) The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 19: 16-27
  • Mazzolari E, Forino C, Guerci S, Imberti L, Lanfranchi A, Porta F, Notarangelo LD (2007) Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 120: 892-899
  • McCarty D, Fu H, Monahan P, Toulson C, Naik P, Samulski R (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118
  • McClements ME, MacLaren RE (2013) Gene therapy for retinal disease. Transl Res 161: 241-254
  • McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ (2010) The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 327: 879-883
  • Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S Li C, Galloway G, et al (2010) Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437
  • Merten O-W, Charrier S, Laroudie N, Fauchille S, Dugué C, Jenny C, Audit M, Zanta-Boussif M-A, Chautard H, Radrizzani M, et al (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22: 343-356
  • Miller N (2012) Glybera and the future of gene therapy in the European Union. Nat Rev Drug Discov 11: 419
  • Mingozzi F, High KA (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122: 23-36
  • Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2: E234
  • Modlich U, Bohne J, Schmidt M, von Kalle C, Knöss S, Schambach A, Baum C (2006) Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108: 2545-2553
  • Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, et al (2009) Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919 -1928
  • Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM (1990) Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood 76: 2153-2158
  • Montini E, Biffi A, Calabria A, Biasco L, Cesani M, Benedicenti F, Plati T, Leo S, Neduva V, Zanetti G, et al (2013) Integration site analysis in a clinical trial of lentiviral vector based hematopoietic stem cell gene therapy for metachromatic leukodystrophy. An 18 month follow-up. Mol Ther 21: s119
  • Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, et al (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975
  • Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, et al (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696
  • Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E, Ryser MF, Haria S, Thrasher AJ, Baum C, et al (2009) Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 16: 111-118
  • Mukherjee S, Thrasher AJ (2013) Gene therapy for PIDs: progress, pitfalls and prospects. Gene 525: 174-181
  • Mussolino C, Cathomen T (2013) RNA guides genome engineering. Nat Biotechnol 31: 208-209
  • Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye T, Cathomen T (2011) A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 39: 9283-9293
  • Nakayama M (2010) Homologous recombination in human iPS and ES cells for use in gene correction therapy. Drug Discov Today 15: 198-202
  • Naldini L (2011) Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315
  • Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365
  • Neven B, Leroy S, Decaluwe H, Le Deist F, Picard C, Moshous D, Mahlaoui N, Debre M, Casanova JL, Dal Cortivo L, et al (2009) Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 113: 4114-4124
  • Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, Hartmann M, Meyer J, Hartmann S, Hansmann M-L, Fehse B, et al (2008) Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286
  • Notarangelo LD (2010) Primary immunodeficiencies. J Allergy Clin Immunol 125: S182-S194
  • Notarangelo LD, Miao CH, Ochs HD (2008) Wiskott–Aldrich syndrome. Curr Opin Hematol 15: 30-36
  • Nowrouzi A, Penaud-Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P, von Kalle C, Snyder RO, Schmidt M (2012) Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 20: 1177-1186
  • Onder TT, Daley GQ (2012) New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev 22: 500-508
  • Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, et al (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409
  • Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, et al (2011) Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 29: 73-78
  • Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146
  • Park J, Singha K, Son S, Kim J, Namgung R, Yun C, Kim W (2012) A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy. Cancer Gene Ther 19: 741-748
  • Perez-Pinera P, Ousterout DG, Gersbach CA (2012) Advances in targeted genome editing. Curr Opin Chem Biol 16: 268-277
  • Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee Y-L (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816
  • Persons DA, Baum C (2011) Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol Ther 19: 229-231
  • Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733
  • Railey MD, Lokhnygina Y, Buckley RH (2009) Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 155: 834.e1-840.e1
  • Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao G-p, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158
  • Raper SE, Yudkoff M, Chirmule N, Gao G-P, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S (2002) A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 13: 163-175
  • Rivat C, Santilli G, Gaspar HB, Thrasher AJ (2012) Gene therapy for primary immunodeficiencies. Hum Gene Ther 23: 668-675
  • Rogers S, Pfuderer P (1968) Use of viruses as carriers of added genetic information. Nature 219: 749-751
  • Roos A-K, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, Bråve A, Wahren B, Pisa P (2009) Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS ONE 4: e7226
  • Roos D (1994) The genetic basis of chronic granulomatous disease. Immunol Rev 138: 121-157
  • Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL (1990) Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578
  • Russell SJ Peng K-W, Bell JC, (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658-670
  • Sadelain M, Papapetrou EP, Bushman FD (2012) Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 12: 51-58
  • Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, Haria S, Parsley KL, Kinnon C, Malech HL, et al (2011) Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 19: 122-132
  • Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, Hernandez RJ, Benedicenti F, Radrizzani M, Salomoni M, et al (2013) Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott–Aldrich syndrome. Mol Ther 21: 175-184
  • Schambach A, Zychlinski D, Ehrnstroem B, Baum C (2013) Biosafety features of lentiviral vectors. Hum Gene Ther 24: 132-142
  • Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, et al (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra153
  • Segal A, West I, Wientjes F, Nugent J, Chavan A, Haley B, Garcia R, Rosen H, Scrace G (1992) Cytochrome b-245 is a flavocytochrome containing FAD and the NADPH-binding site of the microbicidal oxidase of phagocytes. Biochem J 284: 781-788
  • Shen H, Sun T, Ferrari M (2012) Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 19: 367-373
  • Sheridan C (2011) Gene therapy finds its niche. Nat Biotechnol 29: 121-128
  • Shi J, Zheng D (2009) An update on gene therapy in China. Curr Opin Mol Ther 11: 547-553
  • Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, et al (2010) Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204
  • Stewart HJ, Fong-Wong L, Strickland I, Chipchase D, Kelleher M, Stevenson L, Thoree V, McCarthy J, Ralph GS, Mitrophanous KA (2010) A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Hum Gene Ther 22: 357-369
  • Suerth JD, Maetzig T, Brugman MH, Heinz N, Appelt J-U, Kaufmann KB, Schmidt M, Grez M, Modlich U, Baum C, et al (2012) Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol Ther 20: 1022-1032
  • Suzuki N, Yamazaki S, Yamaguchi T, Okabe M, Masaki H, Takaki S, Otsu M, Nakauchi H (2013) Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. Mol Ther 21: 1424-1431
  • Swierczek M, Izsvák Z, Ivics Z (2012) The Sleeping Beauty transposon system for clinical applications. Expert Opin Biol Ther 12: 139-153
  • Tachibana M, Amato P, Sparman M, Gutierrez NM, Tippner-Hedges R, Ma H, Kang E, Fulati A, Lee HS, Sritanaudomchai H, et al (2013) Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153: 1228-1238
  • Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676
  • Thomas ED, Lochte HL, Jr, Cannon JH, Sahler OD, Ferrebee JW (1959) Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38: 1709-1716
  • Tilemann L, Ishikawa K, Weber T, Hajjar RJ (2012) Gene therapy for heart failure. Circ Res 110: 777-793
  • Titman P, Pink E, Skucek E, O'Hanlon K, Cole TJ, Gaspar J, Xu-Bayford J, Jones A, Thrasher AJ, Davies EG, et al (2008) Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 112: 3907-3913
  • Vago L, Oliveira G, Bondanza A, Noviello M, Soldati C, Ghio D, Brigida I, Greco R, Lupo Stanghellini MT, Peccatori J, et al (2012) T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood 120: 1820-1830
  • van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, Español T, Fischer A, Kurenko-Deptuch M, Mouy R, et al (2009) Chronic granulomatous disease: the European experience. PLoS ONE 4: e5234
  • Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153: 910-918
  • Wang Z, Rao DD, Senzer N, Nemunaitis J (2011) RNA interference and cancer therapy. Pharm Res 28: 2983-2995
  • Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH (1997) Viable offspring derived from fetal and adult mammalian cells. Nature 385: 810-813
  • Wilson JM (2005) Gendicine: the first commercial gene therapy product. Hum Gene Ther 16: 1014-1015
  • Wirth T, Parker N, Ylä-Herttuala S (2013) History of gene therapy. Gene 525: 162-169
  • Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE (2006) Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12: 348-353
  • Yang L, Xiao X (2013) Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution. Virol J 10: 1-8
  • Ylä-Herttuala S (2012) Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 20: 1831-1832
  • Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920
  • Zhang L, Thrasher AJ, Gaspar HB (2013) Current progress on gene therapy for primary immunodeficiencies. Gene Ther DOI: 10.1038/gt.2013.21
  • Zhou Q, Buchholz CJ (2013) Cell type specific gene delivery by lentiviral vectors: new options in immunotherapy. Oncoimmunology 2: 0-1
  • Zou J, Mali P, Huang X, Dowey SN, Cheng L (2011) Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118: 4599-4608
  • Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E, Mishra A, Baum C (2008) Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16: 718-725